Trial Profile
A Phase II Study of MK-8669 When Administered as Maintenance Therapy to Japanese Patients With Metastatic Bone or Soft-tissue Sarcomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Bone cancer; Soft tissue sarcoma
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Nov 2012 Planned End Date changed from 1 Oct 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 11 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.